The Priority Review

Clinical trials Brief

Ribupatide shows significant weight loss in adults without diabetes

In a phase 3 trial of 567 participants, once-weekly ribupatide produced least-squares mean weight reductions of -10.7%, -16.4%, and -17.7% at 48 weeks for 2, 4, and 6 mg doses versus -1.4% with placebo. Gastrointestinal events were the most frequent adverse events, occurring in 47.9%, 58.2%, and 63.1% of participants at the three doses.

Primary source

PubMed record of a Phase III journal article, November 16, 2026

Once-Weekly Ribupatide for Weight Loss in Adults in China With Overweight or Obesity: The GEMINI-1 Randomized Clinical Trial.

Read the source: Once-Weekly Ribupatide for Weight Loss in Adults in China With Overweight or Obesity: The GEMINI-1 Randomized Clinical Trial. pubmed.ncbi.nlm.nih.gov

Machine-summarized from the source above; not independently reported. How we use automation